Exelixis I

Exelixis is a pre-commercial stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. In 2008, the company was ready to begin partnering discussions on several of its therapeutics. However, the company’s depleted cash position left it vulnerable in negotiations with larger and well capitalized partners.